메뉴 건너뛰기




Volumn 24, Issue 2, 2013, Pages 96-100

Ustekinumab in nail psoriasis: An open-label, uncontrolled, nonrandomized study

Author keywords

Nail psoriasis; Nail Psoriasis Severity Index (NAPSI); Ustekinumab

Indexed keywords

USTEKINUMAB;

EID: 84875362883     PISSN: 09546634     EISSN: 14711753     Source Type: Journal    
DOI: 10.3109/09546634.2011.607796     Document Type: Article
Times cited : (41)

References (27)
  • 1
    • 0030445353 scopus 로고    scopus 로고
    • Psoriasis of the nails associated with disability in a large number of patients: Results of a recent interview with 1,728 patients
    • De Jong EM, Seegers BA, Gulinck MK, Boezeman JB, Van De Kerkhof PC. Psoriasis of the nails associated with disability in a large number of patients: results of a recent interview with 1,728 patients. Dermatology. 1996;193:300- 303.
    • (1996) Dermatology , vol.193 , pp. 300-303
    • De Jong, E.M.1    Seegers, B.A.2    Gulinck, M.K.3    Boezeman, J.B.4    Van De Kerkhof, P.C.5
  • 3
    • 64849102147 scopus 로고    scopus 로고
    • Nail psoriasis and biologics
    • Noiles K, Vender R. Nail psoriasis and biologics. J Cutan Med Surg. 2009;13:1-5.
    • (2009) J Cutan Med Surg , vol.13 , pp. 1-5
    • Noiles, K.1    Vender, R.2
  • 4
    • 69049113992 scopus 로고    scopus 로고
    • Approach to managing patients with nail psoriasis
    • Reich K. Approach to managing patients with nail psoriasis. J Eur Acad Dermatol Venereol 2009;23:15-21.
    • (2009) J Eur Acad Dermatol Venereol , vol.23 , pp. 15-21
    • Reich, K.1
  • 5
    • 63049083901 scopus 로고    scopus 로고
    • Management of psoriatic nail disease
    • De BD. Management of psoriatic nail disease. Semin Cutan Med Surg. 2009;28:39-43.
    • (2009) Semin Cutan Med Surg , vol.28 , pp. 39-43
    • De, B.D.1
  • 6
    • 70449379640 scopus 로고    scopus 로고
    • Psoriatic nail disease: Quality of life and treatment
    • Gupta AK, Cooper EA. Psoriatic nail disease: quality of life and treatment. J Cutan Med Surg. 2009;13:S102-S106.
    • (2009) J Cutan Med Surg , vol.13
    • Gupta, A.K.1    Cooper, E.A.2
  • 7
    • 34147106954 scopus 로고    scopus 로고
    • Biological therapy and nail psoriasis
    • DOI 10.1111/j.1529-8019.2007.00112.x
    • Lawry M. Biological therapy and nail psoriasis. Dermatol Ther. 2007;20:60-67. (Pubitemid 46568378)
    • (2007) Dermatologic Therapy , vol.20 , Issue.1 , pp. 60-67
    • Lawry, M.1
  • 9
    • 72449136160 scopus 로고    scopus 로고
    • Marked improvement in nail psoriasis during treatment with adalimumab
    • Irla N, Yawalkar N. Marked improvement in nail psoriasis during treatment with adalimumab. Dermatology 2009;219: 353-356.
    • (2009) Dermatology , vol.219 , pp. 353-356
    • Irla, N.1    Yawalkar, N.2
  • 10
    • 67651148328 scopus 로고    scopus 로고
    • Sustained improvement in joint pain and nail symptoms with etanercept therapy in patients with moderate- to-severe psoriasis
    • Luger TA, Barker J, Lambert J, Yang S, Robertson D, Foehl J, et al. Sustained improvement in joint pain and nail symptoms with etanercept therapy in patients with moderate- to-severe psoriasis. J Eur Acad Dermatol Venereol. 2009; 23:896-904.
    • (2009) J Eur Acad Dermatol Venereol , vol.23 , pp. 896-904
    • Luger, T.A.1    Barker, J.2    Lambert, J.3    Yang, S.4    Robertson, D.5    Foehl, J.6
  • 11
    • 78349273658 scopus 로고    scopus 로고
    • Ustekinumab for rapid treatment of nail psoriasis
    • Rallis E, Kintzoglou S, Verros C. Ustekinumab for rapid treatment of nail psoriasis. Arch Dermatol. 2010;146:1315- 1316.
    • (2010) Arch Dermatol , vol.146 , pp. 1315-1316
    • Rallis, E.1    Kintzoglou, S.2    Verros, C.3
  • 12
    • 77956343215 scopus 로고    scopus 로고
    • Skin and nail responses after 1 year of infliximab therapy in patients with moderate-to-severe psoriasis: A retrospective analysis of the EXPRESS Trial
    • Reich K, Ortonne JP, Kerkmann U, Wang Y, Saurat JH, Papp K, et al. Skin and nail responses after 1 year of infliximab therapy in patients with moderate-to-severe psoriasis: a retrospective analysis of the EXPRESS Trial. Dermatology. 2010;221:172-178.
    • (2010) Dermatology , vol.221 , pp. 172-178
    • Reich, K.1    Ortonne, J.P.2    Kerkmann, U.3    Wang, Y.4    Saurat, J.H.5    Papp, K.6
  • 13
    • 38349097035 scopus 로고    scopus 로고
    • Baseline nail disease in patients with moderate to severe psoriasis and response to treatment with infliximab during 1 year
    • Rich P, Griffiths CE, Reich K, Nestle FO, Scher RK, Li S, et al. Baseline nail disease in patients with moderate to severe psoriasis and response to treatment with infliximab during 1 year. J Am Acad Dermatol. 2008;58:224-231.
    • (2008) J Am Acad Dermatol , vol.58 , pp. 224-231
    • Rich, P.1    Griffiths, C.E.2    Reich, K.3    Nestle, F.O.4    Scher, R.K.5    Li, S.6
  • 16
    • 0042133222 scopus 로고    scopus 로고
    • Nail Psoriasis Severity Index: A useful tool for evaluation of nail psoriasis
    • DOI 10.1067/S0190-9622(03)00910-1
    • Rich P, Scher RK. Nail Psoriasis Severity Index: a useful tool for evaluation of nail psoriasis. J Am Acad Dermatol. 2003;49: 206-212. (Pubitemid 36951265)
    • (2003) Journal of the American Academy of Dermatology , vol.49 , Issue.2 , pp. 206-212
    • Rich, P.1    Scher, R.K.2
  • 17
    • 33846909827 scopus 로고    scopus 로고
    • Interobserver reliability of the nail psoriasis severity index
    • DOI 10.1111/j.1365-2230.2006.02305.x
    • Aktan S, Ilknur T, Akin C, Ozkan S. Interobserver reliability of the Nail Psoriasis Severity Index. Clin Exp Dermatol. 2007; 32:141-144. (Pubitemid 46233014)
    • (2007) Clinical and Experimental Dermatology , vol.32 , Issue.2 , pp. 141-144
    • Aktan, S.1    Ilknur, T.2    Akin, C.3    Ozkan, S.4
  • 18
    • 38349063393 scopus 로고    scopus 로고
    • The comparison of nail psoriasis severity index with a less time-consuming qualitative system
    • Kacar N, Ergin S, Erdogan BS. The comparison of nail psoriasis severity index with a less time-consuming qualitative system. J Eur Acad Dermatol Venereol. 2008;22: 219-222.
    • (2008) J Eur Acad Dermatol Venereol , vol.22 , pp. 219-222
    • Kacar, N.1    Ergin, S.2    Erdogan, B.S.3
  • 19
    • 67649331684 scopus 로고    scopus 로고
    • Ustekinumab: A new option in psoriasis therapy
    • Chien AL, Elder JT, Ellis CN. Ustekinumab: a new option in psoriasis therapy. Drugs. 2009;69:1141-1152.
    • (2009) Drugs , vol.69 , pp. 1141-1152
    • Chien, A.L.1    Elder, J.T.2    Ellis, C.N.3
  • 20
    • 57749184069 scopus 로고    scopus 로고
    • Etanercept in the treatment and retreatment of psoriasis in daily clinical practice
    • Barrera MV, Habicheyn S, Mendiola MV, Herrera CE. Etanercept in the treatment and retreatment of psoriasis in daily clinical practice. Eur J Dermatol. 2008;18:683-687.
    • (2008) Eur J Dermatol , vol.18 , pp. 683-687
    • Barrera, M.V.1    Habicheyn, S.2    Mendiola, M.V.3    Herrera, C.E.4
  • 22
    • 75749091855 scopus 로고    scopus 로고
    • Effectiveness of adalimumab in treating patients with active psoriatic arthritis and predictors of good clinical responses for arthritis, skin and nail lesions
    • Van den Bosch F, Manger B, Goupille P, McHugh N, Rodevand E, Holck P, et al. Effectiveness of adalimumab in treating patients with active psoriatic arthritis and predictors of good clinical responses for arthritis, skin and nail lesions. Ann Rheum Dis. 2010;69:394-399.
    • (2010) Ann Rheum Dis , vol.69 , pp. 394-399
    • Van Den Bosch, F.1    Manger, B.2    Goupille, P.3    McHugh, N.4    Rodevand, E.5    Holck, P.6
  • 23
    • 26644433889 scopus 로고    scopus 로고
    • Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: A phase III, multicentre, double-blind trial
    • DOI 10.1016/S0140-6736(05)67566-6, PII S0140673605675666
    • Reich K, Nestle FO, Papp K, Ortonne JP, Evans R, Guzzo C, et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet. 2005;366:1367-1374. (Pubitemid 41443403)
    • (2005) Lancet , vol.366 , Issue.9494 , pp. 1367-1374
    • Reich, K.1    Nestle, F.O.2    Papp, K.3    Ortonne, J.-P.4    Evans, R.5    Guzzo, C.6    Li, S.7    Dooley, L.T.8    Griffiths, C.E.M.9
  • 26
    • 43449111187 scopus 로고    scopus 로고
    • Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)
    • DOI 10.1016/S0140-6736(08)60725-4, PII S0140673608607254
    • Leonardi CL, Kimball AB, Papp KA, Yeilding N, Guzzo C, Wang Y, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet. 2008;371: 1665-1674. (Pubitemid 351671883)
    • (2008) The Lancet , vol.371 , Issue.9625 , pp. 1665-1674
    • Leonardi, C.L.1    Kimball, A.B.2    Papp, K.A.3    Yeilding, N.4    Guzzo, C.5    Wang, Y.6    Li, S.7    Dooley, L.T.8    Gordon, K.B.9
  • 27
    • 43449139402 scopus 로고    scopus 로고
    • Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)
    • DOI 10.1016/S0140-6736(08)60726-6, PII S0140673608607266
    • Papp KA, Langley RG, Lebwohl M, Krueger GG, Szapary P, Yeilding N, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet. 2008;371: 1675-1684. (Pubitemid 351671884)
    • (2008) The Lancet , vol.371 , Issue.9625 , pp. 1675-1684
    • Papp, K.A.1    Langley, R.G.2    Lebwohl, M.3    Krueger, G.G.4    Szapary, P.5    Yeilding, N.6    Guzzo, C.7    Hsu, M.-C.8    Wang, Y.9    Li, S.10    Dooley, L.T.11    Reich, K.12


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.